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ABSTRACT 
Faisal. Eman. A., Masters of Science: January: 2020, Public Health 
Title: Is There an Association between Attending Cardiac Rehabilitation Program and 
Health-related Quality of Life among Patients in Qatar?  
Supervisors of Thesis: Dr. Karam Turk-Adawi and Dr. Mohammed Al-Hashemi. 
Background: Cardiovascular Disease (CVD) is the primary cause of death worldwide 
and in Qatar. More patients with CVD are living than before due to medical 
advancements. Therefore, there is an urgent need for secondary prevention strategies. 
Cardiac rehabilitation (CR) is a secondary prevention model of care for the 
management of CVD. Participation in CR programs is effective in improving health-
related quality of life (HRQOL), reducing cardiovascular mortality, morbidity, and 
hospital readmissions.  
Aim: This study aimed to explore the association between attending at least the median 
number of CR sessions and change in HRQOL among patients in Qatar.  
Methods: This is a retrospective cohort study that included all patients who were 
enrolled in the CR program in Qatar from (January 2013 to October 2017), with a total 
of 433 patients. Secondary data were extracted from patients’ records before the CR 
program (pre-CR) and at patient discharge (post-CR). The SF-36 instrument was used 
to assess HRQOL among patients. The four scales of HRQOL that were assessed are 
physical functioning, social functioning, emotional well-being, and general health. 
Results: The study involved 396 (91.4%) males; the mean age was 52.7±9.8 (SD) 
years. There was a statistically significant association between attending at least the 
median number of CR sessions and change in physical functioning scores (95% 
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CI=8.85-29.11/ p-value=0.002), change in social functioning scores (95% CI=0.04-
19.38/ p-value=0.04), change in emotional well-being scores (95% CI= 1.92-22.13/ p-
value=0.02), and change in general health scores (95% CI=0.38-16.42/ p-value= 0.03), 
as compared to attending less than the median number of sessions. The models adjusted 
for age, gender, comorbidities, level of risk, depression, and baseline HRQOL scores. 
 Moreover clinically significant associations were found between attendance and 
improvement in physical functioning, social functioning, emotional well-being, and 
general health, effect sizes= (0.27, 95% CI= 0.11-0.47), (0.29, 95% CI= 0.11-0.47), 
(0.33, 95% CI= 0.17-0.48), (0.35, 95% CI= 0.21-0.50), respectively. 
Conclusion: CR program improved HRQOL, i.e., physical functioning, social 
functioning, emotional well-being, and general health. Therefore, there is a need to 
promote CR utilization among cardiac patients and to implement strategies to keep 
patients in programs. These findings could motivate policymakers to expand CR 
program capacity, as the sole program in Qatar. 
 
Keywords: Cardiac rehabilitation, Health-related Quality of life, Cardiovascular 
disease, Sessions attended. 
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CHAPTER 1: INTRODUCTION 
 
Cardiovascular disease (CVD) is the primary cause of death globally (1). Every 
year, 17.7 million people die due to CVD, contributing to 31% of all deaths worldwide 
(1). In the Eastern Mediterranean Region (EMR), approximately 58.4% of the total 
deaths in 2015 were attributable to non-communicable diseases (NCDs); CVD was the 
leading cause (2). In Qatar, CVD is the number one cause of death among NCDs; it 
accounts for 30% of all deaths (3). Therefore, CVD is a major global, regional, and 
local public health issue. Currently, more patients with CVD are living than before due 
to medical advancement and high technology. Thus, there is an urgent need for 
secondary prevention programs, such as cardiac rehabilitation, to lower the risk of a 
second heart attack. 
Cardiac rehabilitation (CR) is “a comprehensive secondary prevention program 
that is medically supervised to support patients with CVD who went through a cardiac 
event to recover quickly and stay healthy” (4). It consists of seven core components, 
not only exercise (5). These components include “baseline patient assessment, 
nutritional counseling, risk factor management (lipids, hypertension, weight, diabetes, 
and smoking), psychosocial counseling, physical activity counseling, and exercise 
training” (5).  
In literature, it is evident that participation in a CR program is essential in 
improving health-related quality of life (HRQOL), reducing cardiovascular mortality, 
morbidity, and hospital readmissions (6-9). A systematic review and meta-analysis 
showed that participation in the CR program lowers cardiovascular mortality by 26% 
and hospital admissions by 18% (7). 
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In Qatar, there is only one CR program, which was established in 2013. To the 
best of our knowledge, there has been no study that has explored any associations 
between cardiac rehabilitation and patient health outcomes. Therefore, this 
retrospective cohort study aimed to explore the association between attending the CR 
program (attending at least the median number of sessions) and HRQOL among 
patients in Qatar.  
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CHAPTER 2: LITERATURE REVIEW 
 
  The literature review is presented in eight sections: the first section addresses 
the burden of cardiovascular disease: globally, in the EMR and Qatar; the second 
section discusses modifiable risk factors and non-modifiable risk factors of 
cardiovascular diseases; the third section introduces CR program; the fourth section 
focuses on the core components of CR program; the fifth section addresses the different 
phases of CR program; the sixth section explains the benefits of participation in CR 
programs; the seventh section introduces definitions, instruments, and scales of 
HRQOL, the eighth section discusses the factors associated with HRQOL; and lastly 
the ninth section emphasizes on the benefits of participation in CR program on 
HRQOL. 
2.1 Burden of Cardiovascular Disease 
 According to the World Health Organization (WHO), cardiovascular disease  
“is the name for the group of disorders of heart and blood vessels, and include: 
hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular 
disease, heart failure, rheumatic heart disease, congenital heart disease, and 
cardiomyopathies” (10). CVD  is the leading cause of death globally (1). Every year, 
17.7 million people die due to CVD, contributing to 31% of total deaths worldwide (1). 
Around 85% of all CVD deaths are due to strokes and heart attacks; more than 75% of 
these deaths occur in low-income and middle-income countries (1). In the EMR, nearly 
58.4% of the total deaths in 2015 were due to non-communicable diseases, where CVD 
was the primary cause (2); it accounted for 27.4% of total deaths and is projected to 
increase to 32.1% by 2030 (2). Similarly, CVD was the primary cause of disability as 
it was responsible for 9.2% of total disability-adjusted life years (2). 
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In Qatar, CVD is the primary cause of death; 30 % of all deaths are due to CVD 
(3). For instance, for Qatari males aged 20-44 years, CVD mortality was 8.3 per 
100,000, and 4.1 per 100,000 for non-Qatari males (3). Among Qatari males above the 
age of 45 years, CVD mortality increased significantly to 247 per 100,000 (3). 
Therefore, CVD is a major global, regional, and local public health issue. Moreover, 
because of advanced technology and medical advancement in CVD treatment, more 
patients with CVD are living than before. Thus, there is an urgent need for secondary 
prevention programs (cardiac rehabilitation) to reduce the risk of myocardial re-
infarction. 
2.2 Risk Factors of Cardiovascular Disease 
There are two main risk factors of CVD; modifiable and non-modifiable risk 
factors. The non-modifiable risk factors mostly include age, ethnicity, sex, and family 
history of cardiovascular disease (11). For instance, African Caribbean people have an 
elevated risk of developing hypertension than that of the population (11). CVD burden 
could be reduced by addressing modifiable risk factors including overweight and 
obesity, diabetes, hypertension, hyperlipidemia, physical inactivity, consumption of 
unhealthy diet, harmful use of alcohol, and tobacco use (11, 12). Globally, almost three 
million people die each year due to overweight or obesity (13). Many prospective 
studies have shown an association between overweight and CVD mortality and 
morbidity (12). Furthermore, obesity is highly associated with main CVD risk factors 
such as hypertension, dyslipidemia, and type 2 diabetes (13-17). 
Annually, almost six million people die due to tobacco use and passive smoking. 
Smoking is responsible for almost 10% of CVD (19). Besides, many studies have 
shown that regular physical activity lowers the risk of dying of coronary heart disease 
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(12). Furthermore, unhealthy dietary consumption of high levels of salt, tans-fats, 
saturated fats, and cholesterol, and low consumption of fish, vegetables, and fruits 
elevate the risk of CVD (12). Additionally, the harmful use of alcohol affects the heart 
muscle and is associated with an elevated risk of CVD (12). CR program is a 
multidisciplinary health care model for chronic disease management that addresses 
CVD modifiable risk factors in order to promote secondary prevention of CVD (5). 
2.3 Definition of Cardiac Rehabilitation 
Cardiac rehabilitation is “a comprehensive secondary prevention program that 
is medically supervised to support patients with CVD who went through a cardiac event 
to recover quickly and stay healthy” (4).  
2.4 Core Components of Cardiac Rehabilitation Program     
The American Association of Cardiovascular and Pulmonary Rehabilitation, the 
American Heart Association and the European Association for Cardiovascular 
Prevention & Rehabilitation endorsed a set of evidence-based CR core components that 
reduce CVD  risk and disability and promote healthy behaviors and healthy lifestyle (5) 
(20), which are the theoretical foundations used in CR programs. Cardiac rehabilitation 
programs do not consist only of exercise training, although it is one of its core 
components. However, comprehensive CR programs are beyond that. According to 
Balady et al. (2007), the core components of CR programs include (5) : 
 Baseline Patient Assessment: a review of the medical history, physical 
examination through assessment of cardiopulmonary systems, and 
assessment perceived HRQOL. 
 Nutritional Counseling: measure daily caloric intake of saturated fats, 
cholesterol, and sodium, evaluate dietary behaviors, and define targets for 
nutrition interventions. 
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 Weight Management: assess weight, height, and waist circumference, for 
patients with Body Mass Index (BMI) > 25km/m2 and/or waist > 40 inches 
in men and >35 inches in women, determine weight goals and establish a 
comprehensive program. 
 Blood Pressure Management: test blood pressure at rest in ≥ 2 appointments, 
and evaluate current compliance to treatment. 
 Lipid Management: evaluate compliance to lipid-lowering medication, 
obtain fasting measures of triglycerides, high-density lipoprotein, total 
cholesterol, and low-density lipoprotein, and re-examine lipid profiles at 4-
6 weeks post-hospitalization. 
 Diabetes Management: a review of the medical record to check the existence 
or absence of diabetes in patients, assess the history of complications, and 
recent glycosylated hemoglobin and fasting plasma glucose. 
 Tobacco Cessation: evaluate the patient’s smoking status, readiness to 
change, and update status. 
 Psychosocial Management: detect psychosocial distress and ascertain the 
use of psychotropic medications. 
 Physical Activity Counseling: identify the present physical activity level, 
assess activities related to age and gender, and assess willingness to change. 
 Exercise Training: evaluate heart rate, signs, symptoms, exercise capacity, 
and risk stratify to identify the level of monitoring needed during exercise 
training. 
 
 
 
  
7 
 
2.5 Phases of Cardiac Rehabilitation Program 
Cardiac rehabilitation program consists of three  phases: 
 Phase I: also known as inpatient CR, which starts following a CVD 
event, i.e., myocardial infarction to provide rehabilitative and preventive 
services to hospitalized patients (21). 
 Phase II: it starts within 1-3 weeks post-hospitalization, it includes 
electrocardiographic monitoring of patients in an outpatient setting for 
the first 3-6 months post-hospitalization (21).  
 Phase III: deliverers long-term rehabilitative and preventive service for 
patients in an outpatient setting (21) 
For the CR program that is available in Qatar, only phase I and phase II are offered. 
This study is based on data obtained from patients in phase II at the program. 
2.6 Benefits of Participation in Cardiac Rehabilitation Programs 
The benefits of CR are well-documented in the literature. Many studies have 
established a dose-response relationship among patients who attended more number of 
CR sessions and lower mortality as compared to patients who attended a fewer number 
of sessions (22) (23) (24). A study was conducted to assess improvements in the median 
attendance of CR sessions and the risk myocardial infarction or death (25). The study 
revealed that an increase in the median number of sessions attended was associated with 
an approximate 5-8% reduced risk myocardial infarction and death (25). Another study 
has shown that for each further CR session attended, there was a decrease of 1% in 
mortality among CR participants (26). 
A systematic review and meta-analysis of 34 randomized controlled trials were 
conducted to study the effect of exercise-based CR among post-myocardial infarction 
patients. The study revealed that patients who participated in CR had a lower risk of 
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all-cause mortality (OR=0.74, 95%CI: 0.58-0.95), cardiac mortality (OR 0.64, 95%CI: 
0.46-0.88), and re-infarction (OR=0.53, 95%CI: 0.38-0.76) (6). Besides, CR had a 
positive influence on cardiovascular risk factors, including the lipid profile, weight, 
blood pressure, and smoking (6). A meta-analysis of 71 randomized controlled trials of 
patients with coronary heart disease showed that exercise-based CR reduced 
hospitalization by a mean of 31%, cardiac mortality by a mean of 20%, and all-cause 
mortality by a mean of 19%. Moreover, it had a significant decrease in systolic blood 
pressure, triglycerides, and total cholesterol (27). 
A systematic review and meta-analysis of 63 studies was conducted to update 
the Cochrane systematic review and meta-analysis of exercise-based cardiac 
rehabilitation for coronary heart disease indicated that CR resulted in a reduction in 
cardiovascular mortality (RR=0.74; 95% CI: 0.64- 0.86) as well as the risk of hospital 
admissions (RR=0.82; 95% CI: 0.70- 0.96) (7). Moreover, several studies revealed 
increased levels of HRQOL among patients who participated in CR compared to those 
who did not participate (7). A study was conducted in Iran to investigate the effect of 
attending a different number of CR sessions on exercise capacity among patients with 
coronary artery disease (28). The study showed that there was a statistically significant 
increase in exercise training energy expenditure in the group of patients who attended 
10-24 sessions as compared to patients who attended 5-10 sessions (28).  
A review of the advantages of participation in CR in high-middle- and low-
income countries showed that those who participated in CR had a significantly higher 
progression in HRQOL scores compared to non-participant (29). Additionally, a study 
conducted among elderly patients to assess the association between the dose of CR 
sessions attended and the risk of myocardial infarction (MI) and death revealed an 
inverse dose-response relationship; as the number of sessions increases, the risk of 
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death and MI decreases (30). For instance, patients who attended 36 sessions had a 14% 
lower risk of death, (hazard ratio=0.86; 95%CI: 0.77-0.97) as well as a 12% lower risk 
of MI (hazard ratio=0.88; 95%CI: 0.83-0.93) as compared to patients who attended 24 
sessions (30). Moreover, those patients (who attended 36 sessions) had a 22% lower 
risk of death and a 23% lower risk of MI as compared to those who attended 12 sessions 
(30). Compared to patients who attended 1 session only, the risk of death was reduced 
by 47%, and the risk of MI was reduced by 31% among patients who attended 36 
sessions (30). 
2.7 Health-related Quality of Life (HRQOL) 
2.7.1 Definition 
There seems to be no single definition of HRQOL; however, most experts 
agreed that the common definition considered levels of physical, social, mental, role 
functioning, abilities, perceptions, relationships, life satisfaction, and well-being (31) 
(32). According to Bowling, HRQOL is defined as “optimum levels of mental, physical, 
role (e.g., work, parent, career) and social functioning, including relationships, and 
perceptions of health, fitness, life satisfaction, and well-being” (31). 
2.7.2 Instruments and Scales 
Several instruments are used to assess HRQOL. For example, the EQ-5D tool 
was developed by the EuroQol group to provide a generic measure of health status (33). 
There are three versions of the instrument, EQ-5D-5L, EQ-5D-3L and EQ-5D-Y, the 
most commonly used one to measure HRQOL is the EQ-5D-3L which consists of two 
parts, the first part is a descriptive part on the five dimensions of health which are: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression (33). Each 
of these dimensions has three levels where the respondent can choose from: no 
problems, some problems, extreme problems (33). The second part of the instrument is 
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the visual analog scale where the respondent can mark his/her health status on that day 
on a numerical scale from 0-100, where 0 represents worst health and 100 represents 
the best health (33). Another tool that is used to measure HRQOL is the CDC HRQOL-
14 “Healthy Days Measure” (34). It has been used since 1993 to assess both physical 
and mental HRQOL (34). It consists of 14 questions divided into 3 modules the first 
module assesses healthy days (4 questions), the second one assesses activity limitations 
(5 questions), and the third module assesses healthy days symptoms (5 questions) (34). 
 Moreover, The 36-Item Short-Form Health Survey (SF-36), which is a self-
administered, comprehensive and one of the most frequently used instruments to 
measure physical and mental HRQOL (35). It was developed by RAND, a non-profit 
research organization for the medical outcomes study (35). Managed care organizations 
widely use it in order to maintain routine assessment and monitoring of care outcomes 
among adult patients (35). In CR programs, it is commonly used to assess HRQOL 
among patients attending the programs. It includes eight scales: “physical functioning, 
role limitations due to physical health, role limitations due to emotional problems, 
energy/fatigue, emotional well-being, social functioning, pain, and general health” (36).  
A systematic review of the following databases, Cinahil, EMBASE, Cochrane, and 
Psychinfo, assessed the use of SF-36 in CR (37). The review results showed that SF-36 
is a valid and sensitive instrument and appropriate to be used among CR patients (37).  
Scoring SF-36 is done in two steps; firstly, coded values are given to each 
response category for all the 36 items. Each item is scored between 0 to 100, where 0 
represents the least score of health status, and 100 represents the highest score of health 
status (36). Secondly, the average of all items is calculated to produce the eight scale 
scores (36). 
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2.8 Factors Associated with Health-related Quality of Life  
Several factors in the literature are found to be associated with HRQOL among 
patients with CVD. Most of these factors were inversely associated with HRQOL. For 
instance, studies have shown that comorbidities, such as diabetes, hypertension, and 
musculoskeletal disorders, were associated with low HRQOL scores (38-41). Other 
studies demonstrated that depression and smoking were associated with reduced 
HRQOL (42-47). Moreover, socio-demographic factors such as gender and age were 
also associated with HRQOL. As there was an inverse association between age and 
HRQOL (48, 49). Other studies have shown that there were gender differences in 
HRQOL. In general, women tend to have lower improvements in HRQOL post- CR 
compared to men (50, 51). 
2.9 Benefits of Participation in the CR Program on Health-related Quality of Life  
A systematic review and meta-analysis of 41 randomized controlled trials with 
11,747 patients evaluated the effectiveness of CR on HRQOL scales in patients with 
coronary artery disease (8). The results indicated that CR improved HRQOL in the 
following scales: physical, standardized mean change (SMC)= (0.47, 95%CI: 0.31-
0.81), emotional SMC= (0.37, 95% CI: -0.02.31-0.77), and social SMC=(0.31, 95% CI: 
-0.06-0.32) (8). Another study was conducted to explore the association between 
attending the CR program and HRQOL and resuming work. Results revealed that CR 
participants had significantly higher scores in three scales of SF-36 questionnaire; 
general health, social functioning, and physical functioning (52). Additionally, a study 
from Switzerland included patients with heart failure who participated in CR for 12 
weeks (53). HRQOL was measured at baseline and program discharge using the SF-36 
questionnaire (53). The study results showed that HRQOL improved significantly in 
the physical functioning scale (p-value< 0.0001), role-functioning scale (p-value< 
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0.05), and mental component score (p-value< 0.0001) (53).  
In the EMR, few studies have investigated the association between CR and 
HRQOL, mostly in Iran. A quasi-experimental pre-post study was carried out in Iran to 
assess the effect of a comprehensive cardiac rehabilitation program on HRQOL among 
patients with coronary artery disease (9). A paired t-test was performed to compare 
variables pre and post-CR (9). The study results showed a significant improvement in 
HRQOL scales, including physical functioning, physical limitation, body pain, vitality, 
and general health (p-value< 0.05) (9).   
In Qatar, no study has explored the association between attending CR program 
and HRQOL among patients who enrolled in the sole program in the country. 
Therefore, this study aims to fill this gap by exploring if there is an association between 
attending at least the median number of CR sessions and change in SF-36 scales i.e., 
physical functioning, social functioning, emotional well-being, and general health. 
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CHAPTER 3: METHODOLOGY 
 
3.1 Research Objectives 
The main objective is to explore the association between attending at least the 
median number of sessions and change in HRQOL among patients enrolled in the CR 
program in Qatar, specifically: 
a. To explore the association between attending at least the median number of 
sessions and change in physical functioning scores among CR participants in 
Qatar. 
b. To explore the association between attending at least the median number of 
sessions and change in social functioning scores among CR participants in 
Qatar. 
c. To explore the association between attending at least the median number of 
sessions and change in emotional well-being scores among CR participants in 
Qatar. 
d. To explore the association between attending at least the median number of 
sessions and change in general health scores among CR participants in Qatar. 
3.2 Research Questions 
The main research question is, “Is there an association between attending at 
least the median number of sessions and change in HRQOL among patients enrolled in 
the CR program in Qatar?” The present study addressed four scales of the HRQOL as 
follows:  
a. Is there an association between attending at least the median number of 
sessions and the change in physical functioning scores among CR participants 
in Qatar? 
  
14 
 
b. Is there an association between attending at least the median number of 
sessions and the change in social functioning scores among CR participants in 
Qatar? 
c. Is there an association between attending at least the median number of 
sessions and change in emotional well-being scores among CR participants in 
Qatar? 
d. Is there an association between attending at least the median number of 
sessions and change in general health scores among CR participants in Qatar? 
3.3 Research Hypothesis 
The main hypothesis is, “There is an association between attending at least the 
median number of sessions of and change in HRQOL among CR participants in Qatar.” 
The study included two sub-hypotheses: 
a. There is an association between attending at least the median number of 
sessions and the change in physical functioning scores among CR participants 
in Qatar. 
b. There is an association between attending at least the median number of 
sessions and the change in social functioning scores among CR participants in 
Qatar. 
c. There is an association between attending at least the median number of 
sessions and the change in emotional well-being scores among CR participants 
in Qatar. 
d. There is an association between attending at least the median number of sessions 
and the change in general health scores among CR participants in Qatar. 
 
 
  
15 
 
3.4 Study Design 
This is an observational retrospective cohort study based on patients’ records 
obtained from the CR program at the Heart Hospital in Qatar. 
3.5 Study Population 
The study sample included all patients who were enrolled in the sole CR 
program in Qatar from January 2013-October, 2017. 
3.6 Source of Data 
CR professionals collected data at patient entry (pre-CR) and patient discharge 
from the program (post-CR). A list of the all patient’s health card numbers was provided 
to us. We accessed patients' electronic medical records, i.e., computerized health 
information system (Cerner) to extract the data on variables of interest. We have 
encountered some issues when extracting our outcome of interest, as sometimes it was 
missing from the patient’s electronic record. Thus, we tracked the paper-based files of 
patients as well to include all the available information and reduce the level of missing 
data. 
1. Patient admitting data included:  
A) Patient demographics: age (in years), gender (male, female), and risk level for 
cardiac events during exercise (low, moderate, high).  
B) Clinical measures: comorbid conditions (diabetes mellitus (DM) (yes, no) 
(hypertension (HTN) (yes, no), and musculoskeletal disorders (yes, no), 
depression (none, mild to moderate, severe), and HRQOL (continuous). 
 2. Patient discharge data:  
these included the same admitting data but after completion of the CR program. 
The SF-36 instrument was used to assess HRQOL among patients attending the 
CR program. It included eight scales: “physical functioning, role limitations due to 
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physical health, role limitations due to emotional problems, energy/fatigue, 
emotional well-being, social functioning, pain, and general health” (36). This study 
focused on four scales, i.e., physical functioning, social functioning, emotional 
well-being, and general health. Our initial plan was to analyze the eight scales; 
however, due to the high level of missing data in the remaining four scales, we 
decided to base our analysis on the aforementioned scales, which had the highest 
level of complete data that would allow us to have meaningful conclusions. 
3.7 Measures 
1. Dependent variable (outcome): change in HRQOL scores for each of the four 
scales (i.e., physical functioning, social functioning, emotional well-being, and 
general health). The change in each scale was computed based on this equation 
= (HRQOL score at program discharge - HRQOL score at program entry). 
HRQOL is a continuous variable with a range of 0-100 scores.  
2. Independent variables: the variable of interest was attending at least the median 
number of CR sessions, i.e., attending at least   23 sessions for this cohort (yes 
/ no). 
In addition, other covariates were entered in the analysis model. These 
covariates included:  
A. Categorical variables: gender (male / female), risk level for cardiac events 
during exercise (low / moderate / high), comorbidities (DM/ HTN / 
musculoskeletal disorders), depression (none/ mild to moderate/ severe).  
B. Continuous variables: age (in years). 
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3.8 Data Analysis 
The data cleaning step was performed before the analysis to ensure that all the 
values are within a plausible range and to detect any imprecise values. Following this 
step, data were coded and labeled appropriately. Variables were coded according to 
well-established cut-off values in the literature. For instance, the median number of CR 
sessions was computed from the number of sessions attended by this cohort, due to 
unavailability of data on cardiac patients who did not enroll in the CR program, we 
were not able to compare our findings with an unexposed group (non-enrollee), as these 
data do not exist. Therefore, we made an internal comparison group to explore this 
relationship when attending at least a certain cut-off value, which is the median number 
of sessions as compared to not attending it. That would make our interpretation of the 
results more pronounce when changes in outcomes i.e., HRQOL are shown in one 
group who attended at least the median number of sessions as compared to another who 
attended less than the median. Categorizing the number of CR sessions into the median 
was also documented in the literature in several studies (54, 55) (25). Other studies 
categorized the number of CR sessions into four categories from 1 to 11 sessions, 12-
23 sessions, 24-35 sessions and lastly 36 sessions to assess long-term outcomes on a 
large sample size of 30,161 patients (30). 
 Moreover, CR professionals in the heart hospital used the cardiac depression 
scale (CDS) instrument to measure depression. We coded depression based in literature 
as the following cut-off values (1-89) indicates no depression, (90-99) indicates mild to 
moderate, (100 or above) indicates severe depression (56) CDS instrument is shown in 
Appendix H, further, CR professionals used risk level (low, moderate, high) to assess 
the probability of cardiac events during exercise, based on the “American Association 
of Cardiovascular and Pulmonary Rehabilitation’s stratification algorithm for risk of 
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event” (Appendix B). STATA 16 software (57) was used to analyze the data. 
Descriptive analysis was carried out to describe characteristics of the study population, 
i.e., means and standard deviations (SD) for continuous variables, and percentages and 
frequencies for categorical variables. Additionally, the median number of sessions by 
this cohort was computed.   
To examine the four objectives of the study: to explore the association between 
attending at least the median number of sessions and change in each of the following 
dependent variables: physical functioning, social functioning, emotional well-being 
and general health scores, a multiple linear regression analysis was fitted, where 
change in physical functioning scores (continuous variable) was the dependent variable 
in the first model, change in social functioning scores (continuous variable) was the 
dependent variable in the second model, change in emotional well-being scores 
(continuous variable) was the dependent variable in the third model and change in the 
general health scores was the dependent variable in the fourth model. Attending at least 
the median number of sessions (yes/no) was the independent variable of interest in the 
four models. An additional analysis was done using the independent variable as a count 
variable i.e., the number of CR sessions attended with each of the four aforementioned 
outcomes. 
The four models adjusted for potential confounders including: age (in years), 
gender (male / female), risk level for cardiac events during exercise (low / moderate / 
high), comorbidities (DM: yes, no/ HTN: yes, no / musculoskeletal disorders: yes, no), 
and depression (none/ mild to moderate / severe). 
3.9 Multiple Linear Regression Analysis 
 Multiple linear regression analysis was conducted to explore the association 
between attending at least the median number of sessions and change in each of the 
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four scales i.e., physical functioning, social functioning, emotional well-being and 
general health between patients enrolled in the program in Qatar. The purposeful 
selection method was followed. First, univariate analysis was conducted to detect 
variables in our data that were potentially associated with the outcome. For categorical 
variables with more than two levels, Wald statistics p-values were used to assess overall 
significance. Second, clinically significant well-established variables in the literature 
and those with a p-value < 0.25 produced by the univariate analysis were included in 
the initial full model, i.e., age, gender, risk level, diabetes, hypertension, 
musculoskeletal disorders, and depression.  
Third, the regression model was fitted for each outcome separately by entering 
attending at least the median number of sessions (the independent variable) besides the 
aforementioned outcome-related variables. After that, variables with p-values greater 
than 0.05 were dropped except clinically essential variables in the literature; therefore, 
a simpler model was fitted for each outcome. Further, the initial full model was 
compared with the simpler model using the likelihood ratio test (LRT) to decide which 
model fits the data better.   
Finally, multiple linear regression diagnostics were performed for each of the 
final physical functioning, social functioning, emotional well-being, and general health 
models to assess unusual and influential data, normality of residuals, heteroscedasticity, 
multi-collinearity, and model specifications to ensure selection of the most appropriate 
model for our data. 
3.10 Potential Reasons for Missing Data 
 Descriptive statistics showed missing data on some variables. Missing values 
were detected in five variables; percentages of missing for each variable are as follows; 
depression (42.8%), change in physical functioning scores (71.3%), change in social 
functioning scores (71.3%), change in emotional well-being scores (71.3%) and change 
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in general health scores (71.3%). There could be several factors underlying the issue of 
missing values in our dataset. These reasons could be divided into patients-related 
factors and organizational factors. Firstly, for the patient-related factors, since the SF-
36 is a self-administered survey some patients might not feel encouraged answering all 
its parts fully. Therefore, they might tend to skip part of it and leave it blank, and that 
is a common issue in self-administered surveys in general. In addition, although some 
patients might have answered the survey fully, however, when they show up for their 
last session they forget to bring it back and they did not fill it again in the program due 
to time constraints (as informed by CR staff based on their observations). Second, for 
the organizational factors, CR professionals might be overloaded with the routine 
practice; they might not have enough time to follow-up regularly patients who do not 
have their survey filled by their last visit. Moreover, some patients have had a language 
barrier, which hindered them from taking the survey. Therefore, translation of the 
survey to other languages in addition to Arabic and English is needed in order to assess 
HRQOL outcomes in all cardiac patients. 
3.11 Ethical Consideration 
Two institutions approved the protocol of the study: Hamad Medical 
Cooperation Medical Research Center, (MRC-01-18-431), and Qatar University 
Institutional Review Board, (QU-IRB 1068-E/19).   
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CHAPTER 4: RESULTS 
 
Our study consisted of 433 patients. Characteristics of patients at program entry, 
i.e., baseline data, are shown in Table 1. The majority of the patients were males 
(n=396, 91.4%), the mean age of the patients was 52.7 ± 9.8 years (mean ± SD). Of the 
patients, 112 (25.8%) were at high risk, and 67 (15.4%) had depression. As for 
comorbidities, (n=180, 41.5%) of patients had diabetes, (n=185, 42.7%) had 
hypertension and (n=19, 4.3%) had musculoskeletal disorders On a scale from 0-100, 
the highest  mean of baseline scores was in social functioning (77.9±22.1), whereas the 
lowest mean was in general health (67.8±19.2). Scores of physical functioning, social 
functioning, emotional well-being, and general health increased significantly from pre 
to post CR, p-value= 0.004, 0.001, <0.001, <0.001, respectively (Table 2). Missing 
values were detected in five variables; numbers and percentages of missing values are 
depression (n=185, 42.8%), change in physical functioning (n= 309, 71.3%), change in 
social functioning (n= 309, 71.3%), change in emotional well-being (n= 309, 71.3%), 
and change in general health (n= 309, 71.3%). 
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Table 1 
Sociodemographic and Clinical Characteristics at Baseline of All Patients who Attended CR 
Program in Qatar between January 2013- October 2017, (N=433)*: 
*: Unless indicated 
CR: Cardiac rehabilitation 
DM: Diabetes mellitus 
HTN: Hypertension 
SF-36: 36-Item Short-Form Health Survey 
SD: Standard deviation 
 
 
Variable                                                       n (%) or Mean ± SD 
Age (years)  
 
Gender: 
   Male  
   Female                                                     
    
 
Risk level: 
   Low  
   Moderate 
   High 
 
Attending the at least the median 
number of sessions 
    Yes 
     No  
 
Depression: 
  None                                                           
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
  DM: 
  Yes 
   No 
 
  HTN: 
  Yes 
   No  
 
  Musculoskeletal disorders: 
  Yes 
  No 
 
SF-36 Health-related quality of life (scores): 
(n=209) 
   Physical functioning 
   Social functioning  
   Emotional well-being 
   General health  
52.7±9.8 
 
 
396 (91.4) 
37 (8.5) 
 
 
 
151(34.8) 
170 (39.2) 
112 (25.8) 
 
 
 
236 (55.0) 
193 (44.9) 
 
 
181(41.8) 
27 (6.2) 
40 (9.2) 
 
 
 
180 (41.5) 
253 (58.4) 
 
 
185 (42.7) 
248 (57.2) 
 
 
19 (4.3) 
414 (95.6) 
 
 
 
68.8±24.1 
77.8± 22.1 
74.5±17.7 
66.4± 19.6 
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Table 2  
Pre and Post-CR Physical Functioning, Social Functioning, Emotional Well-being, and 
General Health Scores: 
 CR: Cardiac rehabilitation 
*: p-value <0.05 is considered significant 
 CI: Confidence intervals 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Variable                                                                  
       Pre-CR                   Post-CR   
Mean ± SD Mean ± SD 
 Change 
(post-pre) 
95% 
CI 
 p-value  
  
Physical 
functioning  
(n=124) 
 
Social functioning 
(n=124)                                  
 
Emotional well-
being  
(n=124)         
            
               
General health  
(n=125) 
 
 
 
       68.2±24.0               74.9±24.4 
 
 
 
77.9± 22.2              84.5±18.1 
 
 
 
       75.5±17.5               81.3±15.3 
 
 
 
67.8± 19.2              74.6±19.1 
 
 
6.7 
 
 
 
6.5 
 
 
 
5.8 
 
 
 
6.8 
 
 
(2.08-
11.35) 
 
 
(2.66-
10.53) 
 
 
(3.13-
8.57) 
 
 
(4.10-
9.61) 
 
 
 
0.004* 
 
 
 
0.001* 
 
 
 
<0.001* 
 
 
 
<0.001* 
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4.1 Physical Functioning Scale 
4.1.1 Univariate Analysis 
The results of the univariate analysis describing the change in physical 
functioning scores by each variable separately, i.e., one variable at a time, are shown in 
Table 3, variables with a p-value <0.25 were added in the initial full model. These 
variables included attending at least the median number of CR sessions, gender, 
depression, risk level, and diabetes, along with clinically important variables. The 
regression model was fitted, and all variables with p-values >0.05 were eliminated from 
the new simpler model, except the variables that were clinically significant and well-
established in the literature to have important associations with the outcome of interest 
(i.e., change in physical functioning scores). The likelihood ratio test (LRT) showed 
that the new simpler model was better than the initial full model. LRT= 1.68, p-value= 
0.19. 
4.1.2 Multiple Linear Regression 
Adjusted estimates of the change in physical functioning scores by patient 
demographics and clinical characteristics are shown in Table 4. There was a statistically 
significant association between attendance and change in physical functioning scores; 
participants attending at least 23 sessions had a greater improvement in physical 
functioning by 23.98 units compared to those attending less than 23 sessions (95% CI= 
8.85-29.11/ p-value=0.002), adjusting for age, gender, risk level, depression, diabetes, 
hypertension, musculoskeletal disorders, and baseline physical functioning scores.  
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Table 3  
Univariate Analysis of the Change in Physical Functioning Scores by Patient 
Factors† (n=124): 
†: Results in the table were obtained by conducting separate univariate analyses, i.e., the 
dependent variable with each factor listed in the table. 
 CI: Confidence interval 
 DM: Diabetes mellitus, HTN: Hypertension  
  
Patient characteristic             Coefficient           95% CI                  p-value               
 
Attending at least the median 
number of sessions 
   No 
   Yes  
   
Age (years)  
 
Gender  
   Male  
   Female                                                     
 
Risk level  
   Low  
   Moderate 
   High 
 
Depression:(n=107) 
   No                                                         
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
   DM: 
    No 
    Yes 
 
   HTN: 
    No 
   Yes 
    
  Musculoskeletal disorders: 
  No 
  Yes  
 
 
Reference 
15.39                   (5.19-25.59)              0.003                 
 
0.01                     (-0.49-0.53)                0.94                  
 
 
Reference 
24.49                    (-11.00-59.99)            0.17                
 
 
Reference 
12.39                      (-0.09-24.84)                  0.05                  
11.76                    (-2.45-25.98)              0.10               
 
 
Reference 
13.60                        (-6.54-33.75)                 0.18  
-7.02                           (-23.47-9.42)                   0.39                  
 
 
 
Reference 
7.72                           (-3.32-18.77)                  0.16                
 
 
Reference 
-2.23                     (-13.34-8.86)              0.69                
 
 
Reference 
7.28                         (-15.04-29.62)             0.51              
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Table 4 
Adjusted Estimates of the Change in Physical Functioning Scores by Patient 
Demographics and Clinical Characteristics (n=106):  
CI: Confidence interval 
*: p-value <0.05 is considered significant, DM: Diabetes mellitus, HTN: Hypertension  
 
  
Patient characteristic                              Coefficient          95%CI                 p-value               
 
Attending at least the median 
number of sessions 
   No 
   Yes  
   
Age (years) 
 
Gender 
   Male  
   Female                                                     
 
Baseline physical functioning scores 
 
Risk level 
   Low  
   Moderate 
   High 
 
Depression   
   No                                                         
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
   DM: 
   No 
   Yes 
 
   HTN: 
   No    
   Yes 
    
  Musculoskeletal disorders: 
   No  
   Yes  
    
 
 
Reference 
 23.98               (8.85-29.11)               0.002*                                        
 
0.08                  (-0.43-0.61)                   0.74                  
 
 
Reference 
23.65                 (-17.81-65.12)              0.26            
   
0.40                    (0.59-0.21)             <0.001 
 
 
Reference 
-13.48                  (-33.10-6.12)             0.17           
-14.92                  (-39.89-10.05)           0.23          
 
 
Reference 
13.20                    (-6.54-32.95)             0.18             
 -10.09                  (-25.88-5.69)             0.20              
 
 
 
Reference 
10.95                      (-2.63-24.54)            0.11            
 
 
Reference 
-4.42                       (-17.43-8.59)            0.50            
 
 
Reference 
9.74                         (-12.80-32.28)         0.39                                               
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4.1.3 Multiple Linear Regression Diagnostics 
Multiple linear regression diagnostics were conducted; normality of residuals 
analysis showed that residuals were normally distributed, as shown in Figure 5-
Appendix F. Heteroscedasticity was assessed using White’s test and Breusch-Pegan 
test. These tests resulted in a p-value= 0.12 and 0.82, respectively. This supported 
homogeneity of variance because the p-value of the heteroscedasticity test was not 
significant. The regression diagnostics also showed that there was no issue of multi-
collinearity as variance inflation factor (VIF) was <10 for all the variables as shown in 
Appendix G. Finally, we concluded that our model was correctly specified, the p-value 
of the squared predictor= 0.38, which indicated that there was no specification error. 
4.2 Social Functioning Scale 
4.2.1. Univariate Analysis 
The results of the univariate analysis describing the change in social functioning 
scores by each variable separately, i.e., one variable at a time, are shown in Table 5, 
variables with a p-value <0.25 were added in the initial full model. These variables 
included depression, risk level, and diabetes, along with clinically important variables. 
The regression model was fitted, and all variables with p-values >0.05 were eliminated 
from the new simpler model, except the variables that were clinically significant and 
well-established in the literature to have important associations with the outcome of 
interest (i.e., change in social functioning scores). The likelihood ratio test (LRT) 
showed that the new simpler model was better than the initial full model. LRT=0.01, p-
value=0.90. 
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4.2.2. Multiple Linear Regression 
Adjusted estimates of the change in social functioning scores by patient 
demographics and clinical characteristics are shown in Table 6. There was a statistically 
significant association between attendance and change in social functioning scores; 
participants attending at least 23 sessions had a greater improvement in social 
functioning by  9.96 units compared to those attending less than 23 sessions (95% 
CI=0.04-19.38/ p-value=0.04), adjusting for age, gender, risk level, depression, 
diabetes, hypertension, musculoskeletal disorders, and baseline social functioning 
scores.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
29 
 
Table 5  
Univariate Analysis of the Change in Social Functioning Scores by Patient Factors† 
(n=124): 
 †: Results in the table were obtained by conducting separate univariate analyses, i.e., the 
dependent variable with each factor listed in the table. 
CI: Confidence interval 
DM: Diabetes mellitus, HTN: Hypertension  
  
Patient characteristic             Coefficient            95% CI                p-value 
 
Attending at least the median 
number of sessions 
   No 
   Yes  
   
Age (years) 
 
Gender 
   Male  
   Female                                                     
 
Risk level  
   Low  
   Moderate 
   High 
 
Depression:(n=107) 
   No                                                         
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
   DM: 
    No 
    Yes 
 
   HTN: 
    No 
   Yes 
    
  Musculoskeletal disorders: 
  No 
  Yes  
 
 
Reference 
 0.86                     (-6.94-8.66)               0.82                 
 
-0.18                     (-0.55-0.18)               0.32                   
 
 
Reference 
-6.76                    (-32.44-18.92)              0.6                
 
 
Reference 
 -3.71                   (-12.73-5.30)               0.41                  
-8.46                        (-18.76-1.83)                    0.1               
 
 
Reference 
12.45                   (-2.89-27.81)               0.11                
-5.5                       (-18.04-7.02)              0.38                  
 
 
 
Reference          
-7.78                          (-15.66-0.09)                0.05 
 
 
Reference 
-4.09                      (-12.04-3.86)             0.31                
 
 
Reference 
-1.37                     (-17.45-14.70)            0.86              
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Table 6 
Adjusted Estimates of the Change in Social Functioning Scores by Patient 
Demographics and Clinical Characteristics (n=106):  
CI: Confidence interval 
*: p-value <0.05 is considered significant, DM: Diabetes mellitus, HTN: Hypertension  
 
  
Patient characteristic                              Coefficient          95%CI                     p-value               
 
Attending at least the median 
number of sessions 
   No 
   Yes  
   
Age (years) 
 
Gender 
   Male  
   Female                                                     
 
Baseline social functioning scores  
 
Risk level 
   Low  
   Moderate 
   High 
 
Depression   
   No                                                         
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
   DM: 
   No 
   Yes 
 
   HTN: 
   No    
   Yes 
    
  Musculoskeletal disorders: 
   No  
   Yes  
    
 
 
Reference 
9.69                     (0.04-19.38)              0.04*              
 
-0.01                    (-0.35-0.26)               0.77                  
 
 
Reference 
-2.45                     (-22.93-18.03)           0.81            
   
0.64                       (0.79-0.50)            <0.001 
 
 
Reference 
-8.42                     (-18.35-1.50)              0.09           
-11.93                   (-24.77-0.90)              0.06          
 
 
Reference 
0.71                     (-9.29-10.70)               0.88              
-20.48                    (-29.52,-11.44)              0.22             
 
 
 
Reference 
-4.05                     (-10.98-2.87)              0.24           
 
 
Reference 
-0.25                      (-6.98-6.46)               0.93            
 
 
Reference 
-6.76                       (-17.92-4.38)            0.23                                                
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4.2.3 Multiple Linear Regression Diagnostics 
Multiple linear regression diagnostics were conducted; normality of residuals 
analysis showed that residuals were normally distributed, as shown in Figure 6-
Appendix F . Heteroscedasticity was assessed using White’s test and Breusch-Pegan 
test. These tests resulted in a p-value= 0.83 and 0.61, respectively. This supported 
homogeneity of variance because the p-value of the heteroscedasticity test was not 
significant. The regression diagnostics also showed that there was no issue of multi-
collinearity as variance inflation factor (VIF) was <10 for all the variables as shown in 
Appendix G.  Finally, we concluded that our model was correctly specified, the p-value 
of the squared predictor= 0.22, which indicated that there was no specification error. 
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4.3 Emotional well-being Scale 
4.3.1 Univariate Analysis 
The results of the univariate analysis describing the change emotional well-
being scores by each variable separately, i.e., one variable at a time, are shown in Table 
7. Variables with a p-value <0.25 were added in the initial full model. These variables 
included attending at least the median number of sessions, gender, risk level, and 
depression, along with clinically important variables. The regression model was fitted, 
and all variables with p-values >0.05 were eliminated from the new simpler model, 
except the variables that were clinically significant and well-established in the literature 
to have important associations with the outcome of interest (i.e., change in emotional 
well-being scores). The likelihood ratio test (LRT) showed that the new simpler model 
was better than the initial full model. LRT=0.37, p-value=0.54. 
4.3.2 Multiple Linear Regression 
Adjusted estimates of the change in emotional well-being scores by patient 
demographics and clinical characteristics are shown in Table 8. There was a statistically 
significant association between attendance and change in emotional well-being scores; 
participants attending at least 23 sessions had 12.02 units greater improvement in 
emotional well-being compared to those attending less than 23 sessions (95% CI=1.92-
22.13/ p-value=0.02), adjusting for age, gender, risk level, depression, diabetes, 
hypertension, musculoskeletal disorders, and baseline emotional well-being scores. 
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Table 7 
Univariate Analysis of the Change in Emotional Well-being Scores by Patient 
Factors† (n=124): 
†: Results in the table were obtained by conducting separate univariate analyses, i.e., the 
dependent variable with each factor listed in the table. 
CI: Confidence interval 
DM: Diabetes mellitus, HTN: Hypertension  
 
  
Patient characteristic                                                                   Coefficient  95% CI                     p-value 
Attending at least the median 
number of sessions 
   No 
   Yes  
   
Age 
 
Gender: 
   Male   
   Female                                                     
    
Risk level: 
   Low                                               
   Moderate 
   High 
 
Depression:(n=107) 
  None                                                          
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
  DM: 
  No 
  Yes 
   
  HTN: 
  No 
  Yes 
 
  Musculoskeletal disorders 
  No 
  Yes  
 
 
 
Reference 
18.84                 (10.42-27.25)                 <0.001                
 
-0.09                (-0.51-0.32)                       0.6                              
 
 
Reference 
-21.86               (-50.72-6.98)                 0.13 
 
 
Reference 
20.09                     (10.41-29.76)                <0.001                
11.61                 (0.56-22.65)                    0.04 
 
 
Reference 
9.03                   (-5.55-23.62)                     0.2 
-3.09                 (-15.0-8.81)                      0.6 
 
 
 
Reference 
4.26                    (-4.76-13.30)                   0.3 
 
 
Reference 
2.99                    (-6.03-12.02)                  0.5 
 
 
Reference 
7.21                    (-10.95-25.37)              0.43 
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Table 8 
 
Adjusted Estimates of Change in Emotional Well-being Scores by Patient 
Demographics and Clinical Characteristics (n=124): 
 
CI: Confidence interval 
 *: p-value <0.05 is considered significant, DM: Diabetes mellitus, HTN: Hypertension  
 
 
 
 
Patient characteristic                                                                   Coefficient     95% CI                  p-value 
Attending at least the median 
number of sessions: 
  No 
  Yes  
   
Age 
 
Gender 
   Male   
   Female                                                      
 
Baseline emotional well-being scores 
 
Risk level 
   Low                                               
   Moderate 
   High 
 
Depression  
  None                                                          
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
 DM: 
 No 
 Yes 
 
 HTN: 
 No 
Yes  
 
 Musculoskeletal disorders 
  No 
  Yes  
 
 
 
Reference 
12.02                      (1.92-22.13)              0.02*              
 
-0.04                     (-0.50-0.40)               0.83                  
 
Reference 
-15.0                     (-45.41-15.41)           0.33              
 
 
0.40                           (0.58-0.23)              <0.001 
 
 
Reference 
6.30                        (8.08-20.68)             0.38               
-5.09                       (-23.41-13.2)            0.58               
 
 
Reference 
 11.10                       (-3.37-25.58)          0.13             
 -0.84                          (-12.42-10.73)          0.88             
 
 
 
Reference 
-1.00                          (-10.96-8.96)        0.84           
                         
 
Reference 
1.60                            (-7.94-11.15)        0.73          
  
 
Reference 
 9.87                           (-6.65-26.41)        0.23          
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4.3.3 Multiple Linear Regression Diagnostics 
Multiple linear regression diagnostics were conducted; normality of residuals 
analysis showed that residuals were normally distributed, as shown in Figure 7-
Appendix F. Heteroscedasticity was assessed using White’s test and Breusch-Pegan 
test. These tests resulted in a p-value= 0.49 and 0.25, respectively. This supported 
homogeneity of variance because the p-value of the heteroscedasticity test was not 
significant. The regression diagnostics also showed that there was no issue of multi-
collinearity as variance inflation factor (VIF) was <10 for all the variables as shown in 
Appendix G. Finally, we concluded that our model was correctly specified, the p-value 
of the squared predictor= 0.53, which indicated that there was no specification error.  
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4.4 General Health Scale 
4.4.1 Univariate Analysis 
The results of the univariate analysis describing the change in general health 
scores by each variable separately, i.e., one variable at a time, are shown in Table 9, 
variables with a p-value <0.25 were added in the initial full model. These variables 
included attending at least the median number of sessions, age risk level, depression, 
and diabetes, along with clinically important variables. The regression model was fitted, 
and all variables with p-values >0.05 were eliminated from the new simpler model, 
except the variables that were clinically significant and well-established in the literature 
to have important associations with the outcome of interest (i.e., change in general 
health scores). The likelihood ratio test (LRT) showed that the new simpler model was 
better than the initial full model. LRT=0.21, p-value=0.64. 
4.4.2 Multiple Linear Regression 
Adjusted estimates of the change in general health scores by patient 
demographics and clinical characteristics are shown in Table 10. There was a 
statistically significant association between attendance and change in general health 
scores; participants attending at least 23 sessions had 8.40 units greater improvement 
in general health compared to those attending less than 23 sessions (95% CI=0.38-
16.42/ p-value=0.03), adjusting for age, gender, risk level, depression, diabetes, 
hypertension, musculoskeletal disorders, and baseline general health scores.In addition 
to the statistical significant associations that were found, we found clinically significant 
associations between attendance and improvement in physical functioning, social 
functioning, emotional well-being, and general health, effect sizes= (0.27, 95% CI= 
0.11-0.47), (0.29, 95% CI= 0.11-0.47 ), (0.33, 95% CI= 0.17-0.48), (0.35, 95% CI= 
0.21-0.50), respectively. Effect sizes were computed as follows (mean change in each 
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HRQOL scale overtime/ baseline standard deviation) (66). According to Cohen, an 
effect size of 0.2 is an indicator of minimal clinical significance change (67). McGee et 
al., have shown that among CR patients, an increase in an effect size of 0.3 is an 
indicator of a positive clinical effect (66). 
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Table 9 
Univariate Analysis of the Change in General Health Scores by Patient Factors† 
(n=124): 
†: Results in the table were obtained by conducting separate univariate analyses, i.e., the 
dependent variable with each factor listed in the table. 
CI: Confidence interval 
DM: Diabetes mellitus, HTN: Hypertension  
 
 
  
Patient characteristic                                                                   Coefficient 95%CI                    p-value         
Attending at least the median 
number of sessions: (n=123) 
   No 
   Yes  
   
Age 
 
Gender: 
   Male   
   Female                                                     
    
 
Risk level: 
   Low                                               
   Moderate 
   High 
 
Depression:(n=107) 
  None                                                          
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
  DM: 
  No 
  Yes 
   
  HTN: 
  No 
  Yes 
 
  Musculoskeletal disorders 
  No 
  Yes  
  
 
 
Reference 
3.76                     (-1.84-9.38)           0.18                  
 
-0.16                    (-0.42-0.09)           0.21                  
 
 
Reference 
1.47                      (-16.65-19.60)       0.87              
 
 
 
Reference 
3.84                       (-2.55-10.23)        0.23              
0.98                       (-6.31-8.28)          0.78                  
 
 
Reference 
-1.09                     (-11.19-9.00)         0.83                 
-5.15                     (-13.40-3.08)         0.21               
 
 
 
Reference 
-04.09                     (-9.68-1.50)         0.15              
 
 
Reference 
-2.28                       (-7.89-3.33)         0.42              
 
 
Reference 
-0.02                       (-11.36-11.31)      0.99              
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Table 10 
Adjusted Estimates of the Change in General Health Scores by Patient Demographics 
and Clinical Characteristics (n=106) 
CI: Confidence interval 
 *: p-value <0.05 is considered significant, DM: Diabetes mellitus, HTN: Hypertension  
 
 
 
 
 
 
 
 
Patient characteristic                                                                   Coefficient         95%CI                    p-value 
Attending at least the median 
number of sessions: 
  No 
  Yes  
   
Age 
 
Gender 
   Male   
   Female                                                     
 
Baseline general health scores   
 
Risk level 
   Low                                               
   Moderate 
   High 
 
Depression  
  None                                                          
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
  DM: 
  No 
  Yes 
   
  HTN: 
  No 
  Yes 
 
Musculoskeletal disorders: 
  No 
  Yes  
 
  
 
 
Reference 
8.40                          (0.38-16.42)                   0.03*              
 
0.12                      (-0.13-0.39)                 0.34 
 
 
Reference 
2.66                      (-14.86-20.18)           0.76 
 
0.39                          (0.53-0.25)               <0.001 
 
 
Reference 
 0.93                      (-7.35-9.22)               0.82 
 -3.86                     (-14.42-6.70)             0.46 
 
 
Reference 
-0.19                       (-8.63-8.24)             0.96 
-6.42                       (-13.41-0.57)           0.07 
 
 
 
Reference 
 -1.98                      (-7.71-3.74)             0.49                        
 
 
Reference 
-1.06                      (-6.58-4.46)              0.70 
 
 
Reference 
-6.29                      (-15.79-3.21)            0.19 
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4.4.3 Multiple Linear Regression Diagnostics 
Multiple linear regression diagnostics were conducted; normality of residuals 
analysis showed that residuals were normally distributed, as shown in Figure 8-
Appendix F Heteroscedasticity was assessed using White’s test and Breusch-Pegan test. 
These tests resulted in a p-value = (0.48 and 0.92, respectively). This supported 
homogeneity of variance because the p-value of the heteroscedasticity test was not 
significant. The regression diagnostics also showed that there was no issue with multi-
collinearity as variance inflation factor (VIF) was <10 for all the variables as shown in 
Appendix G.  Finally, we concluded that our model was correctly specified, the p-value 
of the squared predictor= 0.38, which indicated that there was no specification error. 
 
A Comparison between the Sociodemographic and Clinical Characteristics of 
Patients with Complete Data and those with Missing Data: 
 As shown in Table 11, 89% (n=275) of those who had missing data on the four 
scales of HRQOL were males, with a mean age and standard deviation of 52.8±9.5 
years. Almost 40% (n=121) were at a moderate-risk level for cardiac events during 
exercise. Over 70% (n=100) of these patients were none depressed. As for 
comorbidities, 42.72% (n=132) had hypertension, 41.42% (n=128) had diabetes, and 
3.56% (n=13) had musculoskeletal disorders. Almost 55% (n=167) of them have 
attended at least the median number of CR sessions. As shown in Table 11, the 
sociodemographic and clinical characteristics of patients who had complete data were 
similar to that of patients with missing data.  
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Table 11 
A Comparison of the Sociodemographic and Clinical Characteristics of Patients who 
had Missing data in Change in Physical Functioning, Social Functioning, Emotional 
well-being and General Health Scores to those with Complete Data, (N=433): 
DM: diabetes mellitus, HTN: hypertension. 
  
Variable                                                       n (%) or Mean ± SD 
 
Missing data  
(n=309) 
n (%) or Mean ± SD 
 
Complete data 
(n=124) 
 
 
Age (years)  
 
Gender: 
   Male  
   Female                                                     
 
Risk level: 
   Low  
   Moderate 
   High 
 
Attending at least the median 
number of sessions 
    Yes 
     No  
 
Depression: 
  None                                                           
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
DM: 
  Yes  
   No 
 
HTN: 
  Yes  
   No 
 
Musculoskeletal disorders:  
  Yes  
  No 
 
52.8±9.5 
 
 
275 (89.0) 
34 (11) 
 
 
106 (34.3) 
121 (39.1) 
82 (26.5) 
 
 
 
 
167 (54.5) 
139 (45.4) 
 
 
100 (70.9) 
17 (12.0) 
24 (17.0) 
 
 
128 (41.42) 
181 (58.58) 
 
 
132 (42.72) 
177 (57.28) 
 
 
11 (3.56) 
298 (96.44) 
52.47±10.65 
 
 
121( 97.58) 
3 (2.42) 
 
 
45 (36.29) 
49 ( 39.52) 
30 ( 24.19) 
 
 
 
 
69 (56.10) 
54 (43.90) 
 
 
81 (75.70)        
10  (9.35)        
16 (14.95)    
 
 
52 (41.94) 
72 (58.06) 
 
 
53 ( 42.74) 
71 (57.26) 
 
 
8 ( 6.45) 
116 (93.55) 
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4.5 Additional Analysis Using the Count Independent Variable 
 Further analysis of the four outcomes i.e., change in physical functioning scores, 
change in social functioning scores, change in emotional well-being scores, and change 
in general health scores using the independent variable i.e., the number of CR sessions 
attended as a count variable was conducted. The results were similar to the 
aforementioned results where we categorized the independent variable into two groups 
i.e., using the median number of sessions. As shown in Tables 13, 15, 17, 19, there was 
a statistically significant association between attendance and change in physical 
functioning scores, change in social functioning scores, change in emotional well-being 
scores and change in general health scores (95% CI=0.01-1.65/ p-value=0.04), (95% 
CI=0.20-1.96/ p-value= 0.01), (95% CI=0.10-1.17/ p-value=0.01) (95% CI=0.09-0.92/ 
p-value=0.01) respectively, adjusting for age, gender, risk level, depression, diabetes, 
hypertension, musculoskeletal disorders and baseline HRQOL scores. 
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4.5.1 Physical Functioning Scale 
Table 12 
Univariate Analysis of the Change in Physical Functioning Scores by Patient Factors† 
(n=124): 
CI: Confidence interval, DM: Diabetes mellitus, HTN: Hypertension  
 
  
Patient characteristic                                                                   Coefficient       95% CI                     p-value 
 
 
Number of sessions attended 
   
Age 
 
Gender: 
   Male   
   Female                                                     
    
Risk level: 
   Low                                               
   Moderate 
   High 
 
Depression:(n=107) 
  None                                                          
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
  DM: 
  No 
  Yes 
   
  HTN: 
  No 
  Yes 
 
  Musculoskeletal disorders: 
  No 
  Yes  
 
 
0.20                     (-0 .26-0.59)                 0.36 
 
-0.14                    (-0.28-0.58)                  0.49 
               
 
Reference 
25.56                    (-4.36-55.49)               0.09                               
 
 
Reference 
-2.94                       (-13.60-7.72)                  0.58 
4.93                     (-7.24-17.10)               0.42 
 
 
Reference 
21.44                      (4.52-38.36)                 0.01 
-3.86                         (-17.67-9.93)                   0.58 
 
 
 
Reference 
5.76                      (-3.60-15.14)              0.22 
 
 
Reference 
 2.66                     (-6.73-12.05)              0.57 
 
 
Reference 
-9.85                     (-28.70-8.99)             0.30 
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Table 13 
Adjusted Estimates of the Change in Physical Functioning Scores by Patient 
Demographics and Clinical Characteristics (n=106): 
CI: Confidence interval 
 *: p-value <0.05 is considered significant, DM: Diabetes mellitus, HTN: Hypertension  
 
  
Patient characteristic             Coefficient            95% CI                p-value 
 
Number of completed sessions  
   
Age (years) 
 
Gender 
   Male  
   Female                                                     
 
Baseline physical functioning scores 
 
Risk level  
   Low  
   Moderate 
   High 
 
Depression:(n=107) 
   No                                                         
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
   DM: 
    No 
    Yes 
 
   HTN: 
    No 
   Yes 
    
  Musculoskeletal disorders: 
  No 
  Yes  
0.83                            (0.01-1.65)                     0.04* 
 
0.09                      (-0.41-0.61)                0.70                   
 
 
Reference 
15.37                      (-18.27-49.01)           0.36                
 
0.43                         (0.63-0.24)          <0.001 
 
 
Reference 
 -0.34                    (-12.29-11.55)             0.95                  
-8.74                     (-18.76-1.83)              0.39               
 
 
Reference 
16.55                    (-0.27-32.79)            0.04*            
-13.19                        (-26.43-0.04)              0.05                  
 
 
 
Reference          
2.05                           (-9.09-13.21)                0.71 
 
 
Reference 
-5.62                      (-16.31-5.06)             0.29                
 
 
Reference 
1.87                       (-16.68-20.43)           0.84              
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4.5.2 Social Functioning Scale 
Table 14 
Univariate Analysis of the Change in Social Functioning Scores by Patient Factors† 
(n=124): 
CI: Confidence interval, DM: Diabetes mellitus, HTN: Hypertension  
 
  
Patient characteristic                                                                   Coefficient  95% CI                      p-value 
 
Number of sessions attended 
   
Age 
 
Gender: 
   Male   
   Female                                                     
    
Risk level: 
   Low                                               
   Moderate 
   High 
 
Depression:(n=107) 
  None                                                          
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
  DM: 
  No 
  Yes 
   
  HTN: 
  No 
  Yes 
 
  Musculoskeletal disorders: 
  No 
  Yes  
 
0.16                  (-0.60-0.27)                      0.44 
 
 
-0.18                (-0.55-0.18)                     0.32 
 
Reference 
-6.76                  (-32.44-18.92)                   0.60                               
 
 
Reference 
-3.71                 (-12.75-3.10)                  0.58 
-8.46                  (-18.76-1.83)                    0.16 
 
 
Reference 
12.45                 (-2.89-27.81)                   0.11 
-5.50                   (-18.04-7.02)                     0.38 
 
 
 
Reference 
-7.78                   (-15.06-0.09)                0.05 
 
 
Reference 
 -4.09                  (-12.04-3.86)                0.31 
 
 
Reference 
-1.37                  (-17.45-14.70)              0.86 
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Table 15 
Adjusted Estimates of the Change in Social Functioning Scores by Patient 
Demographics and Clinical Characteristics (n=106): 
CI: Confidence interval 
 *: p-value <0.05 is considered significant, DM: Diabetes mellitus, HTN: Hypertension  
 
  
Patient characteristic             Coefficient            95% CI                p-value 
 
Number of completed sessions  
   
Age (years) 
 
Gender 
   Male  
   Female                                                     
 
Baseline social functioning scores 
 
Risk level 
   Low  
   Moderate 
   High 
 
Depression:(n=107) 
   No                                                         
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
   DM: 
    No 
    Yes 
 
   HTN: 
    No 
   Yes 
    
  Musculoskeletal disorders: 
  No 
  Yes  
0.87                      (0.20-1.96)                   0.01* 
 
0.05                      (-0.61-0.73)                0.86                   
 
 
Reference 
-21                       (-66.01-22.63)             0.33                
 
0.66                      (0.80-0.52)               <0.001 
 
 
Reference 
14.47                    (-1.20-30.15)               0.07                  
8.69                       (-17.83-35.22)              0.51               
 
 
Reference 
8.59                    (-12.82-30.01)             0.4            
-18.06                        (-35.51, -0.62)             0.04*                  
 
 
 
Reference          
-12.09                          (-26.79-2.61)                0.10 
 
 
Reference 
-8.87                      (-22.95-5.20)             0.21               
 
 
Reference 
-5.28                       (-29.74-19.16)           0.66              
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4.5.3 Emotional Well-Being Scale 
Table 16 
Univariate Analysis of the Change in Emotional Well-being Scores by Patient Factors† 
(n=124): 
CI: Confidence interval, DM: Diabetes mellitus, HTN: Hypertension  
 
  
Patient characteristic                                                                   Coefficient  95% CI                     p-value 
 
 
Number of sessions attended 
   
Age 
 
Gender: 
   Male   
   Female                                                     
    
Risk level: 
   Low                                               
   Moderate 
   High 
 
Depression:(n=107) 
  None                                                          
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
  DM: 
  No 
  Yes 
   
  HTN: 
  No 
  Yes 
 
  Musculoskeletal disorders 
  No 
  Yes  
 
 
0.33                   (0 .06-0.59)                     0.01 
 
  -0.12              (-0.35-0.09)                    0.25 
               
 
Reference 
-15.24                  (-4.36-55.49)                   0.04                               
 
 
Reference 
5.05                    (-0.31-10.42)                  0.01 
6.14                    (0.01-12.27)                    0.86 
 
 
Reference 
18.41                   (10.40-26.42)                   0.01 
0.56                    (-5.97-7.10)                     0.86 
 
 
 
Reference 
0.75                    (-4.05-5.56)                   0.75 
 
 
Reference 
 3.52                   (-1.23-8.27)                   0.14 
 
 
Reference 
-4.25                  (-13.88-5.38)                0.38 
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Table 17 
Adjusted Estimates of the Change in Emotional Well-being Scores by Patient 
Demographics and Clinical Characteristics (n=106) 
CI: Confidence interval 
 *: p-value <0.05 is considered significant, DM: Diabetes mellitus, HTN: Hypertension  
  
Patient characteristic             Coefficient            95% CI                p-value 
 
Number of completed sessions  
   
Age (years) 
 
Gender 
   Male  
   Female                                                     
 
Baseline emotional well-being scores 
 
 
Risk level  
   Low  
   Moderate 
   High 
 
Depression:(n=107) 
   No                                                         
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
   DM: 
    No 
    Yes 
 
   HTN: 
    No 
   Yes 
    
  Musculoskeletal disorders: 
  No 
  Yes  
0.64                          (0.10-1.17)                   0.01* 
 
-0.13                      (-0.46-0.19)                0.41                   
 
 
Reference 
-18.87                    (-40.68-2.93)             0.08                
 
0.38                          (0.05-0.200)           <0.001 
 
 
 
Reference 
7.29                        (-0.42-15.00)                0.06                  
-1.50                       (-14.56-11.54)              0.81               
 
 
Reference 
12.04                     (1.50-22.58)             0.02*            
-3.98                        (-12.57-4.59)              0.35                  
 
 
 
Reference          
-1.90                         (-9.14-5.32)                 0.60 
 
 
Reference 
3.77                      (-3.12-10.70)              0.28               
 
 
Reference 
-6.76                      (-18.79-5.27)             0.26              
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4.5.4 General Health Scale 
Table 18 
Univariate Analysis of the Change in General Health Scores by Patient Factors† 
(n=124): 
CI: Confidence interval, DM: Diabetes mellitus, HTN: Hypertension  
  
Patient characteristic                                                                   Coefficient  95% CI                     p-value 
Number of sessions attended 
   
Age 
 
Gender: 
   Male   
   Female                                                     
    
Risk level: 
   Low                                               
   Moderate 
   High 
 
Depression:(n=107) 
  None                                                          
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
  DM: 
  No 
  Yes 
   
  HTN: 
  No 
  Yes 
 
  Musculoskeletal disorders 
  No 
  Yes  
 
0.30                      (0 .02-0.59)                      0.03 
 
-0.06                 (-0.29-0.17)                   0.61 
               
 
Reference 
-1.17                  (-17.64-15.30)                 0.88                               
 
 
Reference 
7.27                    (1.57-12.9)                    0.01 
4.21                       (-2.29-10.71)                    0.20 
 
 
Reference 
3.91                     (-5.37-13.21)                   0.40 
-1.14                    (-8.73-6.44)                     0.76 
 
 
 
Reference 
-1.91                   (-7.02-3.20)                 0.46 
 
 
Reference 
 -0.85                   (-5.97-4.25)                 0.74 
 
 
Reference 
-2.78                  (-13.07-7.51)                0.59 
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Table 19 
Adjusted Estimates of the Change in General Health Scores by Patient Demographics 
and Clinical Characteristics (n=106): 
CI: Confidence interval 
 *: p-value <0.05 is considered significant, DM: Diabetes mellitus, HTN: Hypertension  
 
 
 
 
 
 
 
Patient characteristic             Coefficient            95% CI                p-value 
 
Number of completed sessions  
   
Age (years) 
 
Gender 
   Male  
   Female                                                     
 
Baseline general health score  
 
Risk level  
   Low  
   Moderate 
   High 
 
Depression:(n=107) 
   No                                                         
  Mild to moderate                                        
  Severe 
 
Comorbidities: 
   DM: 
    No 
    Yes 
 
   HTN: 
    No 
   Yes 
    
  Musculoskeletal disorders: 
  No 
  Yes  
0.51                     (0.09-0.92)                   0.01* 
 
0.12                   (-0.14-0.38)                  0.35                   
 
 
Reference 
1.11                    (-15.99-18.22)              0.89               
 
 
0.39                   (0.53-0.26)                <0.001 
 
Reference 
4.28                   (-1.75-10.32)                 0.16                  
-4.82                  (-15.06-5.41)                  0.35               
 
 
Reference 
-0.12                   (-8.49-8.24)            0.97           
-7.74                         (-14.78,-0.70)                 0.03*                  
  
 
 
Reference          
-2.94                        (-8.61- 2.72)                0.30 
 
 
Reference 
-0.68                       (-8.61-2.72)                0.80               
 
 
Reference 
-6.25                       (-15.68-3.17)                0.19              
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CHAPTER 5: DISCUSSION 
 
5.1 Cardiac Rehabilitation and Health-related Quality of Life 
Due to the global epidemiological transition from communicable diseases to 
non-communicable diseases, a large number of people nowadays are living with NCDs. 
These diseases are multifactorial as several risk factors are associated with its 
occurrence. Primordial and primary prevention of these risk factors is the ideal method 
in some cases; however, with the current medical advancements in healthcare 
technologies and the aging population, more patients live with CVD than before, 
therefore, they require secondary prevention programs to slow their disease progression 
and manage its complications. Prior studies of the highest level of evidence have shown 
that attending CR programs was associated with better health outcomes. For instance, 
it was effective in reducing cardiovascular mortality by 26% and hospital admissions 
by 18% (7). As well as, it showed significant improvements in HRQOL in both physical 
and mental scales (8) 
Health-related quality of life is a subjective topic; it is perceived differently 
from one person to another. Thus, it is challenging to measure and interpret. In the CR 
program, the primary goal is to help patients, who underwent a cardiac event, to recover 
to a healthy status quickly, both physically and mentally. There is a scarcity of studies 
on the association between the number of CR sessions attended and HRQOL globally 
as well as locally. To the best of our knowledge, this was the first study to explore the 
association between the number of CR sessions attended and HRQOL among patients 
in Qatar. 
Our findings which were based on the complete case analysis showed that there 
were a statistically significant associations between attendance of CR program and 
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change in physical functioning scores, change in social functioning scores, change in 
emotional well-being scores, and change in general health scores among participants 
attending at least 23 sessions as compared to those attending less than 23 sessions, 
adjusting for age, gender, risk level, depression, diabetes, hypertension and 
musculoskeletal disorders. Moreover, we found clinically significant associations 
between attendance and improvement in HRQOL. 
5.2 Duration in CR Program and Change in Health-Related Quality of Life 
Due to a lack of studies on the association between the number of CR sessions 
attended and HRQOL, we used duration in the CR program as a proxy to interpret our 
variable of interest, which was the number of CR sessions attended. Eventually, the 
increase in the number of CR sessions attended will result in a longer duration in the 
program, which is organized on the delivery of sessions on fixed days of the week. In 
accordance with our findings, a study aimed to investigate the changes in HRQOL, 
which was assessed at three time points, at the beginning of the CR program, at the end, 
and after 6-months (68). The study revealed statistically significant changes in physical 
and mental scales at the end of the program (36 sessions); however, from the end of the 
program to 6-months, there was no significant improvement, p-value >0.05(68). Similar 
to our results, the aforementioned study showed a significant clinical important 
difference in HRQOL, effect size ≥ 0.5, in the physical functioning scale (68). 
Moreover, Muller-Nordhorn and his colleagues revealed that after a one-year follow-
up of CR patients, significant improvements in HRQOL which were assessed using SF-
36 were shown, p-value< 0.05 (69). 
Additionally, a randomized controlled trial was conducted to investigate the 
dose of CR sessions and HRQOL. The Eight aspects of physical and mental HRQOL 
were measured at baseline and month 6 with the use of the Medical Outcomes Study 
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SF-36 survey. The results of the study showed higher doses of exercise were associated 
with larger improvements in mental and physical aspects HRQOL (70). 
 However, Hevey and his colleagues have compared a 4-week duration (20 
sessions) to a 10-week duration (30 sessions) CR program (71). No significant 
differences in the attendance duration of CR and the HRQOL were detected, p-value 
>0.05 (71). This could be due to the small sample size of the study or because the 
difference between the number of sessions in the two groups was relatively small.  
5.3 Attending Compared to Non-attending CR Program and Change in Health-
related Quality of Life 
In accordance with the findings of this study. An observational study conducted 
in Canada among CR patients who completed 3-month and 6-month CR programs (72). 
HRQOL was assessed using the SF-36 survey (72). After a 12-week duration in the CR 
program, significant improvements occurred in the mental health aspects of HRQOL, 
p-value <0.0001(72). 
A systematic review of 16 randomized controlled trials in nine countries has 
explored the effect of CR intervention on quality of life among patients with coronary 
heart disease; however, there were variations in the findings, as some studies have 
shown significant improvements in some of HRQOL scales. It showed that 
participation in the CR program was effective in improving the quality of life for 
patients with coronary heart disease, p-value <0.05 (73), whereas others did not show 
any statistically significant differences between intervention and control groups (73). 
 Furthermore, a study published in 2018 by Choo and his colleagues aimed to 
explore the effect of CR on HRQOL among Asian patients in Singapore (43). The study 
compared the means and SD of pre-and-post- HRQOL scores and found statistically 
significant differences between pre-and post-scores, p-value <0.0001. Additionally, a 
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clinical trial study was conducted in Iran among patients with acute coronary syndrome 
has shown that in the intervention group, the mean scores in all scales of HRQOL using 
SF-36 tool increased significantly after CR, p-value <0.05, whereas, no significant 
differences were shown between the intervention and control groups in social 
functioning and general health scales, p-value >0.05 (74).  
           A quasi-experimental study before-after study was conducted to assess the effect 
of CR on HRQOL (9). The study results indicated significant improvements in scores 
of all physical scales, including physical functioning, general health as well as 
improvement in social functioning, especially among older patients and females as 
compared to baseline scores, p-value <0.05 (9). However, the study only compared age 
and sex groups after CR. Other variables might have confounded this association, such 
as depression and comorbidities, as documented in the literature. Duarte Freitas and his 
colleagues have used the SF-36 tool to assess HRQOL after a four-week intensive 
cardiac rehabilitation program (75). The study results revealed that after participation 
in the CR program, physical and mental scores improved significantly p-value <0.0001 
(75). 
        Riaz and his colleagues have used the SF-36 survey to measure patient’s outcomes 
after attending the CR program (76). The results showed a significant improvement in 
the physical capacity score; however, there were no significant improvements in the 
mental capacity score, (p-value=0.96) (76). This could be due to the relatively healthy 
level of mental capacity among patients at baseline. 
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5.4 Study Strengths 
       There were several strengths to our study. The main strength is that we informed 
the CR program director about the quality of data issue; therefore, they are now working 
toward improving the quality of the collected data through establishing of CR registry, 
where the completeness of the data will be monitored regularly. Moreover. In the 
analysis, multiple linear regression models adjusted for well-established confounders 
such as age, gender, level of risk, depression, and comorbidities.  
5.5 Study Limitations 
          One of the limitations of this study is that it was an observational study; it used 
secondary data that were collected before the study initiation; hence, it might not be 
very accurate concerning our objective. Besides, our study was based on secondary data 
that had missing values; however, there were no significant differences between those 
with complete data and those who had missing data on sociodemographic and some 
clinical characteristics. Moreover, the sample size was relatively small Furthermore, 
although we adjusted for potential confounders in our analysis model, the residual 
confounding cannot be eliminated. Moreover, there are several significant variables that 
we should have controlled for to have better understanding of the association with 
health-related of life such as medications, marital status, employment, and level of 
education; however, these variables were not collected from patients, therefore, we 
were not able to obtain it from their records. 
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5.6 Research Implications and Future Recommendations 
     The findings of this study showed that the number of sessions attended was 
associated with improved HRQOL (physical, social, emotional and general health 
scales). The more the number attended, the higher the improvement in those HRQOL 
scales. Therefore, there is a need to promote CR utilization among cardiac patients 
and to implement strategies to keep patients in programs. These findings also could 
motivate policymakers to expand CR program capacity, as the sole program in Qatar. 
     Moreover, this study has revealed the issue of missing data, our recommendation is 
to improve the quality of data collection and entry at the program this could be achieved 
by collecting data directly from patients and entering these data in the system, or by 
following up patients either by telephone calls or mobile messages to collect the 
outcomes of CR. Future research should be carried out while adjusting for other patient 
factors such as medications, social support/family support, marital status, employment, 
and level of education to explore the relationship between these factors and HRQOL. 
The association between attendance and the other four scales of the SF-36 survey could 
also be explored, namely: role limitations due to physical health, role limitations due to 
emotional problems, pain, and energy/fatigue. 
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CHAPTER 6: CONCLUSIONS 
 
 In conclusion, CVD is a major public health issue worldwide. In Qatar, it is the 
number one cause of death among NCDs. Nowadays, due to medical advancements; 
more patients with CVD are living than before. Therefore, this increases the demand 
for the CR program as a secondary prevention tool to reduce the risk of myocardial re-
infarction and its complications. Many studies showed that participation in the CR 
program, where the patient attends at least a certain number of sessions, was associated 
with better health outcomes, including improvement in HRQOL. 
This observational retrospective cohort study was based on secondary data 
extracted from the medical records of all patients who were enrolled in the CR program 
at the heart hospital in Qatar over a period of five consecutive years. The study has 
explored the association between attending at least the median number of  CR sessions 
and change in HRQOL scores while adjusting for other covariates such as age, gender, 
the risk level for cardiac events during exercise, depression, and comorbidities. 
HRQOL was assessed using the SF-36 survey. The study results showed statistically 
significant associations between attending at least the 23  CR sessions and change in 
physical functioning scores, change in social functioning scores, change in emotional 
well-being scores, and change in general health scores. In addition, there were minimal 
clinically significant associations between attendance and improvement in HRQOL. 
CR professionals should consider immediate action regarding the quality of data 
collected to minimize missing values. Future research should be carried out on larger 
sample size, addressing the other four scales of SF-36 survey, while adjusting for other 
factors that were not available in this dataset to explore its relationship with HRQOL, 
if any. 
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APPENDICES 
APPENDIX A: Short-Form Health Survey (SF-36) 
RAND 36-Item Health Survey 1.0 Questionnaire Items 
1. In general, would you say your health is: 
Excellent 1 
Very good  2 
Good 3 
Fair 4 
Poor                              5                       
 
2. Compared to one year ago, how would you rate your health in general now? 
 
1 - Much better now than one year ago 
2 - Somewhat better now than one year ago 
3 - About the same 
4 - Somewhat worse now than one year ago 
5 - Much worse now than one year ago 
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The following items are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much?  
(Circle One Number on Each Line)  
      Yes, Limited a Lot             Yes, Limited a Little                      No, Not limited at 
All  
3. Vigorous 
activities, such as 
running, lifting heavy 
objects, participating 
in strenuous sports  
[1] [2]  3 
4. Moderate 
activities, such as 
moving a table, 
pushing a vacuum 
cleaner, bowling, or 
playing golf  
[1]  [2]  3 
5. Lifting or carrying 
groceries  
[1]  [2]  3 
6. Climbing several 
flights of stairs  
[1]  [2]  3 
7. Climbing one flight 
of stairs  
[1]  [2]  3 
8. Bending, kneeling, 
or stooping  
[1]  [2]  3 
9. Walking more than 
a mile  
[1]  [2]  3 
10. Walking several 
blocks  
[1]  [2]  3 
11. Walking one 
block  
[1]  [2]  3 
12. Bathing or dressing 
myself  
[1]  [2]  3 
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During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health?  
(Circle One Number on Each Line)  
                                                                               Yes                               No  
13. Cut down the amount of 
time you spent on work or 
other activities  
1  2  
14. Accomplished less than 
you would like  
1  2  
15. Were limited in the kind of 
work or other activities  
1  2  
16. Had difficulty performing 
the work or other activities (for 
example, it took extra effort)  
1  2  
 
During the past 4 weeks, have you had any of the following problems with 
your work or 
other regular daily activities as a result of any emotional problems (such as 
feeling 
depressed or anxious)? 
Yes No 
17. Cut down the amount of time you spent on work or other activities     1                  2 
18. Accomplished less than you would like                                                1                 2 
19. Didn't do work or other activities as carefully as usual                           1                 2  
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20. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbours, 
or groups?  
(Circle One Number)  
Not at all 1  
Slightly 2  
Moderately 3  
Quite a bit 4  
Extremely 5  
21. How much bodily pain have you had during the past 4 weeks?  
(Circle One Number)  
None 1  
Very mild 2  
Mild 3  
Moderate 4  
Severe 5  
Very severe 6  
22. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?  
(Circle One Number)  
Not at all 1  
A little bit 2  
Moderately 3  
Quite a bit 4  
Extremely 5  
Note: The WSIB acknowledges that the RAND 36-Item Short Form Health Survey was developed at RAND as part of the Medical Outcomes 
Study. 
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These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling.  
How much of the time during the past 4 weeks . . .  
(Circle One Number on Each Line)  
All of the 
Time  
Most of the 
Time  
A Good Bit of 
the Time  
Some of the 
Time  
A Little of the 
Time  
None of the 
Time  
23. Did you 
feel full of 
pep?  
1  2  3  4  5  6  
24. Have 
you been a 
very 
nervous 
person?  
1  2  3  4  5  6  
25. Have 
you felt so 
down in the 
dumps that 
nothing 
could cheer 
you up?  
1  2  3  4  5  6  
26. Have 
you felt 
calm and 
peaceful?  
1  2  3  4  5  6  
27. Did you 
have a lot 
of energy?  
1  2  3  4  5  6  
28. Have 
you felt 
downheart
ed and 
blue?  
1  2  3  4  5  6  
29. Did you 
feel worn 
out?  
1  2  3  4  5  6  
30. Have 
you been a 
happy 
person?  
1  2  3  4  5  6  
31. Did you 
feel tired?  
1  2  3  4  5  6  
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32. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)?  
(Circle One Number)  
All of the time 1  
Most of the time 2  
Some of the time 3  
A little of the time 4  
None of the time 5  
How TRUE or FALSE is each of the following statements for you.  
(Circle One Number on Each Line)  
Definitely True  Mostly True  Don’t Know  Mostly False  Definitely False  
33. I seem to 
get sick a little 
easier than 
other people  
1  2  3  4  5  
34. I am as 
healthy as 
anybody I 
know  
1  2  3  4  5  
35. I expect 
my health to 
get worse  
1  2  3  4  5  
36. My health 
is excellent  
1  2  3  4  5  
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APPENDIX B: AACVPR Stratification Algorithm for Risk of Event 
 
 AACVPR Stratification Algorithm for Risk of Event  
Not specific solely to exercise events.  
Patient is at HIGH RISK if ANY ONE OR MORE of the following factors are 
present:  
 Left ventricular ejection fraction < 40%  
 Survivor of cardiac arrest or sudden death  
 Complex ventricular dysrhythmias (ventricular tachycardia, frequent 
[> 6/min] multiform PVCs) at rest or with exercise  
 MI or cardiac surgery complicated by cardiogenic shock, CHF, and/or 
signs/symptoms of post-procedure ischemia  
 Abnormal hemodynamics with exercise, especially flat or decreasing 
systolic blood pressure or chronotropic incompetence with 
increasing workload  
 Significant silent ischemia (ST depression 2mm or greater without 
symptoms) with exercise or in recovery  
 Signs/symptoms including angina pectoris, dizziness, 
lightheadedness or dyspnea at low levels of exercise (< 5.0 METs) or 
in recovery  
 Maximal functional capacity less than 5.0 METs*  
 Clinically significant depression or depressive symptoms  
 
Patient is at LOW RISK if ALL of the following factors are present:  
 Left ventricular ejection fraction > 50%  
 No resting or exercise-induced complex dysrhythmias  
 Uncomplicated MI, CABG, angioplasty, atherectomy, or stent:  
 Absence of CHF or signs/symptoms indicating post-event ischemia  
 Normal hemodynamic and ECG responses with exercise and in 
recovery  
 Asymptomatic with exercise or in recovery, including absence of 
angina  
 Maximal functional capacity at least 7.0 METs*  
 Absence of clinical depression or depressive symptoms  
 
Patient is at MODERATE RISK if they meet neither High Risk nor Low Risk 
standards:  
 Left ventricular ejection fraction = 40–50%  
 Signs/symptoms including angina at “moderate” levels of exercise 
(60–75% of maximal functional capacity) or in recovery  
 Mild to moderate silent ischemia (ST depression less than 2mm) with 
exercise or in recovery  
 
*If measured functional capacity is not available, this variable can be excluded from 
the risk stratification process. 
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APPENDIX C: Multiple Linear Regression Diagnostics 
 
 
 
                                                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5: Kernel density plot of residuals of the 
change in physical functioning scores 
 
Figure 6: Kernel density plot of residuals of the 
change in social functioning scores 
 
Figure 7: Kernel density plot of residuals of the 
change in emotional well-being scores 
 
Figure 8: Kernel density plot of residuals of the 
change in general health scores 
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Variance Inflation Factor of Each Covariate: 
 Variance inflation factor of <10 indicates no issue of multi-collinearity 
DM: diabetes mellitus, HTN: hypertension 
  
Variable                                                                  
                              Variance inflation factor 
Attending At least 
the median 
number of 
sessions 
 
Age 
 
Gender  
 
Risk level: 
Moderate 
High 
 
Depression: 
Mild to moderate 
Severe 
 
DM 
 
HTN  
 
Musculoskeletal 
disorders 
 
 
 
 
 
 
3.02 
 
1.43 
 
1.08 
 
 
3.09 
3.81 
 
 
1.13 
1.08 
 
1.53 
 
1.42 
 
 
1.06 
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APPENDIX D: Cardiac Depression Scale (CDS) 
 
Cardiac Depression Scale (CDS) 
This questionnaire consists of a number of statements about the way you feel at 
present. 
Next to each statement there is a rating scale from 1 to 7 for you to indicate how much 
you agree or disagree with the statement  
Strongly disagree 1 2 3 4 5 6 7 Strongly agree  
Please indicate how strongly you agree or disagree with each statement by circling 
one of the numbers on the scale.  
THERE ARE NO RIGHT OR WRONG ANSWERS  
PLEASE ENSURE YOU HAVE COMPLETED ALL 26 ITEMS CDS  
1. I have 
dropped 
many of 
interests 
and 
activities
…  
1  2  3  4  5  6  7  
None dropped All dropped  
2. My 
concentrat
ion is as 
good as it 
ever 
was…  
1  2  3  4  5  6  7  
Very poor Excellent  
concentration concentration  
3. I can’t 
be 
bothered 
doing 
anything 
much…  
1  2  3  4  5  6  7  
Keen to do Can’t be  
things bothered  
4. I get 
pleasure 
from life 
at 
present....  
1  2  3  4  5  6  7  
No pleasure Great pleasure  
 
